ESMO 2026: Moderna’s Vaccine Wins, Wall Street Sells — 10 Calls From Madrid

Moderna and Merck's individualized mRNA cancer vaccine just won its first Phase 3 — and the stock fell sharply the same day. How can a scientific breakthrough be a commercial disappointment?

In this special ESMO 2026 edition of The Oncology Deep Dive, we cut through the noise from Madrid: 10 headline calls, what happened, why it matters for patients and portfolios, and the debates echoing through the halls.

🔹 mRNA vaccine wins in melanoma. INTerpath-001 (intismeran + Keytruda) cut the risk of recurrence or death by 42% after surgery. Practice-changing, or a melanoma-only success with a 6–9 week manufacturing wait?

🔹 Kisqali's benefit keeps growing. Six-year NATALEE data in early HR+/HER2- breast cancer show a survival gain that widens years after patients stop the drug.

🔹 Small cell lung cancer breaks through. Tarlatamab + durvalumab (DeLLphi-305) helps patients live about eight and a half months longer, but can community oncologists manage the immune side effects?

🔹 A head-to-head KRAS cage match. Roche's divarasib beats the first-generation G12C drugs in Krascendo 1, with survival and liver-safety advantages.

🔹 Blocking the tumor's detour. Osimertinib + savolitinib (SAFFRON) beats chemo in MET-driven resistant lung cancer. Targeted roadblocks or ADC smart bombs?

🔹 Merck's TROP2 ADC wins twice. Sac-TMT + Keytruda in PD-L1-low lung cancer, and sac-TMT alone in advanced endometrial cancer after IO, where survival had stagnated for decades.

🔹 Gastric cancer's survival paradox. AstraZeneca's Claudin 18.2 ADC doubles survival even though progression-free survival missed. How?

🔹 Ivonescimab beats durvalumab head-to-head in biliary tract cancer (HARMONi-GI1). But can a China-only trial change US practice?

🔹 Chemo-free surgery bookends in bladder cancer. Durvalumab + enfortumab vedotin (VOLGA) for patients too frail for cisplatin.

The takeaway: oncology is moving its most powerful weapons into the earliest stages of disease, trying to cure cancer on the first attempt rather than salvage it at the end.

For clinicians, investors and anyone who wants clear, jargon-free oncology news every Monday. Follow the show so you don't miss next week's briefing.

#ESMO2026 #Oncology #CancerResearch #mRNA #Moderna #Merck #ADC #LungCancer #BreastCancer #Biotech

Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

Chapters:
00:00 Moderna's vaccine wins, Wall Street sells
00:25 Welcome to our ESMO 2026 special
00:43 INTerpath-001: mRNA vaccine wins in melanoma
01:04 The individualized "wanted poster"
01:54 Why the stock fell
02:49 Debate: practice-changing or melanoma-only?
03:24 NATALEE: Kisqali's six-year survival data
04:07 A benefit that grows after stopping the drug
04:51 DeLLphi-305: tarlatamab in small cell lung cancer
05:52 The catch: cytokine release syndrome
06:29 Krascendo 1: divarasib vs. first-gen KRAS drugs
07:19 Liver safety and the expert split
07:58 SAFFRON: osimertinib + savolitinib
08:50 Targeted roadblocks vs. ADC smart bombs
09:15 Sac-TMT + Keytruda in PD-L1-low lung cancer
10:02 Merck's Keytruda moat
10:19 TroFuse-005: sac-TMT in endometrial cancer
11:27 Claudin 18.2 ADC in gastric cancer
12:18 Survival without PFS: the paradox
12:55 HARMONi-GI1: ivonescimab beats durvalumab
13:42 Can a China-only trial change US practice?
14:03 VOLGA: chemo-free bookends in bladder cancer
15:08 The takeaway: curing cancer on the first try
15:47 Sign-off